Rivercell raises $25M to build an AI model of how cells respond to drugs
The Paris company will film living cells through each experiment to build the data its model needs. Rivercell was started in 2025 by Cardiologs founder Yann Fleureau, with Owkin’s Eric Durand.
Via TNW | Investors-funding
Paris start-up Rivercell has raised a $25M seed round to build an AI model that predicts how human cells respond to drugs and genetic changes. HV led the round, with HCVC, Alven and Bpifrance Digital Venture taking part, the company said on Wednesday.
The money will pay for Rivercell’s data platform, a bigger wet lab in Paris and the launch of its AI Virtual Cell programme. The company describes the model as a world model of the cell, meaning a…
Courtesy
This story was originally published by TNW | Investors-funding. All rights belong to the original publisher.
Read the original on thenextweb.com ↗